Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 28 September 2012, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.37 per Ordinary Share, and notional ADSs at a price of $46.52 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2012 to 30 September 2012:
Non Executive Director |
Ordinary Shares |
American Depositary Shares (ADSs) |
Sir Christopher Gent |
2,348.643 |
|
Professor Sir Roy Anderson |
456.681 |
|
Dr Stephanie Burns |
|
443.463 |
Stacey Cartwright |
326.200 |
|
Sir Crispin Davis |
1,652.749 |
|
Lynn Elsenhans |
|
570.166 |
Judy Lewent |
|
221.731 |
Sir Deryck Maughan |
|
886.925 |
Dr Daniel Podolsky |
|
855.249 |
Tom de Swaan |
674.148 |
|
Jing Ulrich |
|
158.379 |
Sir Robert Wilson |
456.681 |
|
The Company and the Non-Executive Directors were informed of these allocations on 1 October 2012.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
2 October 2012